Latest total current liabilities for OBLN: $2.1M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Obalon Therapeutics (OBLN) currently reports a total current liabilities of $2.1M as of March 2026. That compares with $4.1M in the prior-year period — down 48.0% year over year. Use the charts on this page to explore Obalon Therapeutics's total current liabilities history and peer comparisons.
Obalon Therapeutics's total current liabilities decreased from $4.1M to $2.1M — a 48.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Obalon Therapeutics reported $2.1M in total current liabilities as of March 2026. That compares with $4.1M in the prior-year period — down 48.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $2.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Obalon Therapeutics, and consider following OBLN for alerts when major investors trade the stock.
Obalon Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $2.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OBLN with unrelated industries.